Tagrisso plus chemotherapy demonstrated strong improvement in progression-free survival for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial

Results support potential for a new treatment option that builds on the benefit of first-line standard of care Tagrisso monotherapy Positive high-level results from the FLAURA2 Phase III trial showed AstraZeneca’s Tagrisso (osimertinib) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared…

Read the full article here

Source: www.astrazeneca.com

Categories: Hem/Oncs, Latest Headlines

Tags: lcsm, PressRelease

Tweets with this article

Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ

☄️#PressRelease The combination of Osimertinib plus chemo showed a strong PFS improvement vs Osi alone for patients with EGFR-mutated advanced lung cancer in FLAURA2 Ph III trial #LCSM 📌2023 will be an historical year for EGFR+ management: stay tuned 🔊 https://t.co/ulRJLY97UV https://t.co/8j2okQGx8w

Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival in HR-positive, HER2-low metastatic breast cancer following one or more lines of endocrine therapy in DESTINY-Breast06 Phase III trial

Positive high-level results from the DESTINY-Breast06 Phase III trial showed that Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival…

Aditya Bardia, MD April 30, 2024

Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival in HR-positive, HER2-low metastatic breast cancer following one or more lines of endocrine therapy in DESTINY-Breast06 Phase III trial

Aditya Bardia, MD April 29, 2024

Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival in HR-positive, HER2-low metastatic breast cancer following one or more lines of endocrine therapy in DESTINY-Breast06 Phase III trial

Aditya Bardia, MD April 29, 2024

Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival in HR-positive, HER2-low metastatic breast cancer following one or more lines of endocrine therapy in DESTINY-Breast06 Phase III trial

Aditya Bardia, MD April 29, 2024

Antibody-drug conjugates in lung and breast cancer: Current evidence and future directions – a position statement from the ETOP IBCSG Partners Foundation

Following the approval of the first antibody-drug conjugates (ADCs) in the early 2000s, development has increased dramatically, with 14 ADCs now approved and >100 in…

Antonio Passaro, MD PhD April 24, 2024

Voydeya approved in the EU as add-on treatment to ravulizumab or eculizumab for adults with the rare disease PNH who have residual haemolytic anaemia

Voydeya (danicopan) has been approved in the European Union (EU) as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal…

April 23, 2024

Antibody-drug conjugates in lung and breast cancer: Current evidence and future directions – a position statement from the ETOP IBCSG Partners Foundation

Following the approval of the first antibody-drug conjugates (ADCs) in the early 2000s, development has increased dramatically, with 14 ADCs now approved and >100 in…

Antonio Passaro, MD PhD April 22, 2024

Cardiovascular Disease | AstraZeneca

Cardiovascular disease is a leading cause of death worldwide. Learn more about our ambition to eliminate risk factors and stop disease progression.

April 6, 2024

Imfinzi significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial

Positive high-level results of the ADRIATIC Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) demonstrated a statistically significant and clinically meaningful improvement in the dual primary…

Rami Manochakian, M.D April 5, 2024

Imfinzi significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial

Rami Manochakian, M.D April 5, 2024

Related Articles